tiprankstipranks
Ideaya Biosciences (DE:30J)
NASDAQ:30J
Germany Market
30J
IDEAYA Biosciences
RESEARCH TOOLSreports

IDEAYA Biosciences (30J) Stock Forecast & Price Target

5 Followers
See the Price Targets and Ratings of:

30J Analyst Ratings

Strong Buy
12Ratings
Strong Buy
11 Buy
1 Hold
0 Sell
Based on 12 analysts giving stock ratings to
IDEAYA
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

30J Stock 12 Month Forecast

Average Price Target

€47.82
▲(74.66% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for IDEAYA Biosciences in the last 3 months. The average price target is €47.82 with a high forecast of €57.87 and a low forecast of €31.56. The average price target represents a 74.66% change from the last price of €27.38.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"€16","37":"€37","58":"€58","26.5":"€26.5","47.5":"€47.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":57.86615934,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€57.87</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.823272181818176,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€47.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.56335964,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€31.56</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,26.5,37,47.5,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.25,34.22047379538461,36.190947590769234,38.16142138615385,40.13189518153846,42.102368976923074,44.072842772307695,46.04331656769231,48.01379036307692,49.98426415846154,51.954737953846156,53.92521174923077,55.89568554461539,{"y":57.86615934,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.25,33.44794401398601,34.64588802797203,35.84383204195804,37.041776055944055,38.239720069930065,39.43766408391608,40.63560809790209,41.83355211188811,43.03149612587412,44.22944013986014,45.42738415384615,46.625328167832166,{"y":47.823272181818176,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.25,32.197181510769234,32.14436302153846,32.091544532307694,32.03872604307692,31.985907553846154,31.933089064615384,31.880270575384618,31.827452086153848,31.774633596923078,31.721815107692308,31.66899661846154,31.61617812923077,{"y":31.56335964,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.66,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.22,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.25,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€57.87Average Price Target€47.82Lowest Price Target€31.56
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on DE:30J
Leonid Timashev
RBC Capital
RBC Capital
€46.47→€42.08
Buy
53.71%
Upside
Reiterated
07/07/26
Ideaya Biosciences price target lowered to $48 from $53 at RBC CapitalIdeaya Biosciences price target lowered to $48 from $53 at RBC Capital
Truist Financial Analyst forecast on DE:30J
Gregory Renza
Truist Financial
Truist Financial
€56.99→€55.24
Buy
101.74%
Upside
Reiterated
07/07/26
Ideaya Biosciences price target lowered to $63 from $65 at TruistIdeaya Biosciences price target lowered to $63 from $65 at Truist
Mizuho Securities Analyst forecast on DE:30J
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
€26.5→€43.84
Buy
60.11%
Upside
Reiterated
06/16/26
Analysts Offer Insights on Healthcare Companies: Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) and IDEAYA Biosciences (NASDAQ: IDYA)
LifeSci Capital Analyst forecast on DE:30J
Charles Zhu
LifeSci Capital
LifeSci Capital
€56.99→€54.36
Buy
98.54%
Upside
Reiterated
06/15/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wedbush Analyst forecast on DE:30J
Robert Driscoll
Wedbush
Wedbush
€50.85
Buy
85.73%
Upside
Reiterated
06/12/26
Analysts Are Bullish on Top Healthcare Stocks: Warby Parker (WRBY), IDEAYA Biosciences (IDYA)
UBS Analyst forecast on DE:30J
Michael Yee
UBS
UBS
€43.84
Buy
60.11%
Upside
Reiterated
06/09/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and IDEAYA Biosciences (NASDAQ: IDYA)
Goldman Sachs Analyst forecast on DE:30J
Corinne Johnson
Goldman Sachs
Goldman Sachs
€30.69→€31.56
Hold
15.28%
Upside
Reiterated
06/03/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA) and Diaceutics (Other OTC: DIUXF)
Guggenheim Analyst forecast on DE:30J
Paul Jeng
Guggenheim
Guggenheim
€47.35
Buy
72.92%
Upside
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Context Therapeutics (NASDAQ: CNTX), IDEAYA Biosciences (NASDAQ: IDYA) and Edgewise Therapeutics (NASDAQ: EWTX)
J.P. Morgan Analyst forecast on DE:30J
Anupam Rama
J.P. Morgan
J.P. Morgan
€71.02→€57.87
Buy
111.34%
Upside
Reiterated
05/29/26
J.P. Morgan Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)
TD Cowen Analyst forecast on DE:30J
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/05/26
Analysts Are Bullish on Top Healthcare Stocks: Lineage Therap (LCTX), IDEAYA Biosciences (IDYA)
Wells Fargo Analyst forecast on DE:30J
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
€38.58→€42.08
Buy
53.71%
Upside
Reiterated
04/14/26
Wells Fargo Remains a Buy on IDEAYA Biosciences (IDYA)
Citi Analyst forecast on DE:30J
Yigal Nochomovitz
Citi
Citi
€56.99
Buy
108.14%
Upside
Reiterated
04/13/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), IDEAYA Biosciences (NASDAQ: IDYA) and Ligand Pharma (NASDAQ: LGND)
Jefferies Analyst forecast on DE:30J
Maury Raycroft
Jefferies
Jefferies
€27.18→€45.59
Buy
66.51%
Upside
Reiterated
04/05/26
Analysts Offer Insights on Healthcare Companies: UnitedHealth (NYSE: UNH), IDEAYA Biosciences (NASDAQ: IDYA) and Bristol-Myers Squibb (NYSE: BMY)
Barclays Analyst forecast on DE:30J
Peter Lawson
Barclays
Barclays
€35.07
Buy
28.09%
Upside
Reiterated
11/04/25
IDEAYA Biosciences (IDYA) Gets a Buy from Barclays
BTIG Analyst forecast on DE:30J
Justin Zelin
BTIG
BTIG
€54.36
Buy
98.54%
Upside
Reiterated
11/04/25
IDEAYA Biosciences: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on DE:30J
Leonid Timashev
RBC Capital
RBC Capital
€46.47→€42.08
Buy
53.71%
Upside
Reiterated
07/07/26
Ideaya Biosciences price target lowered to $48 from $53 at RBC CapitalIdeaya Biosciences price target lowered to $48 from $53 at RBC Capital
Truist Financial Analyst forecast on DE:30J
Gregory Renza
Truist Financial
Truist Financial
€56.99→€55.24
Buy
101.74%
Upside
Reiterated
07/07/26
Ideaya Biosciences price target lowered to $63 from $65 at TruistIdeaya Biosciences price target lowered to $63 from $65 at Truist
Mizuho Securities Analyst forecast on DE:30J
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
€26.5→€43.84
Buy
60.11%
Upside
Reiterated
06/16/26
Analysts Offer Insights on Healthcare Companies: Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) and IDEAYA Biosciences (NASDAQ: IDYA)
LifeSci Capital Analyst forecast on DE:30J
Charles Zhu
LifeSci Capital
LifeSci Capital
€56.99→€54.36
Buy
98.54%
Upside
Reiterated
06/15/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wedbush Analyst forecast on DE:30J
Robert Driscoll
Wedbush
Wedbush
€50.85
Buy
85.73%
Upside
Reiterated
06/12/26
Analysts Are Bullish on Top Healthcare Stocks: Warby Parker (WRBY), IDEAYA Biosciences (IDYA)
UBS Analyst forecast on DE:30J
Michael Yee
UBS
UBS
€43.84
Buy
60.11%
Upside
Reiterated
06/09/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and IDEAYA Biosciences (NASDAQ: IDYA)
Goldman Sachs Analyst forecast on DE:30J
Corinne Johnson
Goldman Sachs
Goldman Sachs
€30.69→€31.56
Hold
15.28%
Upside
Reiterated
06/03/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA) and Diaceutics (Other OTC: DIUXF)
Guggenheim Analyst forecast on DE:30J
Paul Jeng
Guggenheim
Guggenheim
€47.35
Buy
72.92%
Upside
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Context Therapeutics (NASDAQ: CNTX), IDEAYA Biosciences (NASDAQ: IDYA) and Edgewise Therapeutics (NASDAQ: EWTX)
J.P. Morgan Analyst forecast on DE:30J
Anupam Rama
J.P. Morgan
J.P. Morgan
€71.02→€57.87
Buy
111.34%
Upside
Reiterated
05/29/26
J.P. Morgan Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)
TD Cowen Analyst forecast on DE:30J
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/05/26
Analysts Are Bullish on Top Healthcare Stocks: Lineage Therap (LCTX), IDEAYA Biosciences (IDYA)
Wells Fargo Analyst forecast on DE:30J
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
€38.58→€42.08
Buy
53.71%
Upside
Reiterated
04/14/26
Wells Fargo Remains a Buy on IDEAYA Biosciences (IDYA)
Citi Analyst forecast on DE:30J
Yigal Nochomovitz
Citi
Citi
€56.99
Buy
108.14%
Upside
Reiterated
04/13/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), IDEAYA Biosciences (NASDAQ: IDYA) and Ligand Pharma (NASDAQ: LGND)
Jefferies Analyst forecast on DE:30J
Maury Raycroft
Jefferies
Jefferies
€27.18→€45.59
Buy
66.51%
Upside
Reiterated
04/05/26
Analysts Offer Insights on Healthcare Companies: UnitedHealth (NYSE: UNH), IDEAYA Biosciences (NASDAQ: IDYA) and Bristol-Myers Squibb (NYSE: BMY)
Barclays Analyst forecast on DE:30J
Peter Lawson
Barclays
Barclays
€35.07
Buy
28.09%
Upside
Reiterated
11/04/25
IDEAYA Biosciences (IDYA) Gets a Buy from Barclays
BTIG Analyst forecast on DE:30J
Justin Zelin
BTIG
BTIG
€54.36
Buy
98.54%
Upside
Reiterated
11/04/25
IDEAYA Biosciences: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering IDEAYA Biosciences

3 Months
Charles ZhuLifeSci Capital
Success Rate
18/29 ratings generated profit
62%
Average Return
+11.83%
Copying Charles Zhu's trades and holding each position for 3 Months would result in 62.07% of your transactions generating a profit, with an average return of +11.83% per trade.
1 Year
Charles ZhuLifeSci Capital
Success Rate
25/29 ratings generated profit
86%
Average Return
+45.98%
Copying Charles Zhu's trades and holding each position for 1 Year would result in 86.21% of your transactions generating a profit, with an average return of +45.98% per trade.
2 Years
Graig SuvannavejhMizuho Securities
Success Rate
17/17 ratings generated profit
100%
Average Return
+39.95%
Copying Graig Suvannavejh's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +39.95% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

30J Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
21
29
29
27
15
Buy
15
12
10
4
3
Hold
0
1
1
3
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
36
42
40
34
20
In the current month, 30J has received 18 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 30J average Analyst price target in the past 3 months is 47.82.
Each month's total comprises the sum of three months' worth of ratings.

30J Financial Forecast

30J Earnings Forecast

Next quarter’s earnings estimate for 30J is -€0.92 with a range of -€1.11 to -€0.65. The previous quarter’s EPS was -€0.97. 30J beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 30J has Performed in-line its overall industry.
Next quarter’s earnings estimate for 30J is -€0.92 with a range of -€1.11 to -€0.65. The previous quarter’s EPS was -€0.97. 30J beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 30J has Performed in-line its overall industry.

30J Sales Forecast

Next quarter’s sales forecast for 30J is €6.98M with a range of €0.00 to €34.17M. The previous quarter’s sales results were €5.74M. 30J beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 30J has Performed in-line its overall industry.
Next quarter’s sales forecast for 30J is €6.98M with a range of €0.00 to €34.17M. The previous quarter’s sales results were €5.74M. 30J beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 30J has Performed in-line its overall industry.

30J Stock Forecast FAQ

What is DE:30J’s average 12-month price target, according to analysts?
Based on analyst ratings, Ideaya Biosciences’s 12-month average price target is 47.82.
    What is DE:30J’s upside potential, based on the analysts’ average price target?
    Ideaya Biosciences has 74.66% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Ideaya Biosciences a Buy, Sell or Hold?
          Ideaya Biosciences has a consensus rating of Strong Buy, which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Ideaya Biosciences’s share price target?
            The average share price target for Ideaya Biosciences is 47.82. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €57.87 ,and the lowest forecast is €31.56. The average share price target represents 74.66% Increase from the current price of €27.38.
              What do analysts say about Ideaya Biosciences?
              Ideaya Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of Ideaya Biosciences?
                To buy shares of DE:30J, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.